Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...

The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense competition among Boston hospitals.

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...